Delcath taps Miao as CFO

Delcath Systems  ($DCTH) has named Graham Miao as CFO. David McDonald, who has served as the company's CFO since 2009, will assume the newly created role of executive VP, business development.

Miao joins Delcath from Dun & Bradstreet Corporation, where he served as chief of staff of the Global CFO Organization. Previously, he held the position of executive VP & CFO of Pagoda Pharmaceuticals, a Shanghai-based specialty pharmaceuticals and medical device company focused in urology and allergies. In addition, Miao held positions at Schering-Plough, Pharmacia and J.P. Morgan.

"The timing of Graham Miao's appointment as CFO is part of the planned expansion of our executive leadership team in advance of the expected commercial launch of our Hepatic CHEMOSAT Delivery System at the end of this year," CEO Eamonn Hobbs explained in a statement. "His knowledge of the global pharmaceutical industry landscape and experience in both established and development stage pharmaceutical/medical device companies will bring additional strategic insights as well."

- check out the Delcath announcement

Suggested Articles

Longitude Capital invests in what its founders call “transformative healthcare companies," working in areas they hope will increase quality of life.

The FDA launched a center of excellence to oversee digital health products such as smartphone apps, wearable devices and software-based treatments.

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.